Veit, T. ; Barnikel, M. ; Crispin, A.* ; Kneidinger, N. ; Ceelen, F. ; Arnold, P. ; Munker, D. ; Schmitzer, M. ; Barton, J. ; Schiopu, S. ; Schiller, H. B. ; Frankenberger, M. ; Milger, K. ; Behr, J. ; Neurohr, C.* ; Leuschner, G.
Variability of forced vital capacity in progressive interstitial lung disease: A prospective observational study.
Respir. Res. 21:270 (2020)
BackgroundFibrotic interstitial lung disease (ILD) is often associated with poor outcomes, but has few predictors of progression. Daily home spirometry has been proposed to provide important information about the clinical course of idiopathic pulmonary disease (IPF). However, experience is limited, and home spirometry is not a routine component of patient care in ILD. Using home spirometry, we aimed to investigate the predictive potential of daily measurements of forced vital capacity (FVC) in fibrotic ILD.MethodsIn this prospective observational study, patients with fibrotic ILD and clinical progression were provided with home spirometers for daily measurements over 6 months. Hospital based spirometry was performed after three and 6 months. Disease progression, defined as death, lung transplantation, acute exacerbation or FVC decline >10% relative was assessed in the cohort.ResultsFrom May 2017 until August 2018, we included 47 patients (IPF n=20; non-IPF n=27). Sufficient daily measurements were performed by 85.1% of the study cohort. Among these 40 patients (IPF n=17; non-IPF n=23), who had a meanSD age of 60.7 +/- 11.3years and FVC 64.7 +/- 21.7% predicted (2.4 +/- 0.8L), 12 patients experienced disease progression (death: n= 2; lung transplantation: n=3; acute exacerbation: n=1; FVC decline >10%: n=6). Within the first 28days, a group of patients had high daily variability in FVC, with 60.0% having a variation >= 5%. Patients with disease progression had significantly higher FVC variability than those in the stable group (median variability 8.6% vs. 4.8%; p=0.002). Cox regression identified FVC variability as independently associated with disease progression when controlling for multiple confounding variables (hazard ratio: 1.203; 95% CI:1.050-1.378; p=0.0076).Conclusions Daily home spirometry is feasible in IPF and non-IPF ILD and facilitates the identification of FVC variability, which was associated with disease progression.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Interstitial Lung Disease ; Idiopathic Pulmonary Fibrosis ; Home Spirometry ; Forced Vital Capacity ; Variability ; Disease Progression; Idiopathic Pulmonary-fibrosis; Acute Exacerbations; Guidelines; Validation; Pneumonia; Diagnosis; Prognosis; Risk
Keywords plus
Language
english
Publication Year
2020
Prepublished in Year
HGF-reported in Year
2020
ISSN (print) / ISBN
1465-9921
e-ISSN
1465-993X
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 21,
Issue: 1,
Pages: ,
Article Number: 270
Supplement: ,
Series
Publisher
BioMed Central
Publishing Place
Campus, 4 Crinan St, London N1 9xw, England
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
80000 - German Center for Lung Research
30202 - Environmental Health
Research field(s)
Lung Research
PSP Element(s)
G-501800-810
G-501600-012
G-501600-001
G-501600-002
Grants
Projekt DEAL
German Society "Lungenfibrose e.V"
Friedrich-Baur-Stiftung (Ludwig-Maximilians University Munich)
Boehringer Ingelheim
Copyright
Erfassungsdatum
2020-11-25